Kineta to Host Key Opinion Leader Event on KVA12123: VISTA
SEATTLE, March 06, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused
Globe Newswire6-03-2023, 18:39
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection 22-10-2024, 19:00